- Home>
- Specialties>
- General Medicine>
- Summary and Comment
No Benefit of (Some) NSAIDs in Alzheimer's Disease Progression
Neither rofecoxib nor naproxen prevented cognitive decline in patients with AD.
Epidemiologic associations and results of clinical studies suggest that nonsteroidal anti-inflammatory drugs (NSAIDs) might help prevent or slow the development of Alzheimer's disease (AD; Journal Watch Nov 23 2001). In this multicenter U.S. trial, 351 AD patients (age, >50; Mini-Mental State Exam score, 13-26) were randomized to receive rofecoxib (25 mg daily), naproxen sodium (220 mg twice daily), or placebo. Regular use of medications such as cholinesterase inhibitors, estrogen, aspirin, and vitamin E was allowed.
At 1 year, intent-to-treat analyses using several standardized cognitive measures showed no significant difference in cognitive decline among the 3 groups. Fatigue, dizziness, and hypertension were more common in the treatment groups, as were serious adverse events (e.g., gastrointestinal tract bleeding, stroke, subdural hematoma, myocardial infarction) overall.
Comment: Despite the biologic plausibility of an NSAID-mediated decrease in inflammation and ß-amyloid production in Alzheimer's disease, this study did not show any such benefit with either nonselective or cyclooxygenase (COX)-2 blockage. An editorialist notes that researchers should explore the value of NSAIDs in patients with other types of cognitive dysfunction, differentiate primary prevention from slowing progression in high-risk patients, delineate the potential benefits of COX-1 vs. COX-2 inhibition, and explore the risks and benefits of longer NSAID treatment.
— Thomas L. Schwenk, MD
Published in Journal Watch General Medicine June 27, 2003
Citation(s):
Aisen PS et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial. JAMA 2003 Jun 4; 289:2819-26.
- Original article (Subscription may be required)
- Medline abstract (Free)
Launer LJ. Nonsteroidal anti-inflammatory drugs and Alzheimer disease: What's next? JAMA 2003 Jun 4; 289:2865-7.
- Original article (Subscription may be required)
- Medline abstract (Free)